Ocular Melanoma – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Ocular Melanoma – Drugs In Development, 2023’, provides an overview of the Ocular Melanoma pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Ocular Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Ocular Melanoma and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Ocular Melanoma
- The report reviews pipeline therapeutics for Ocular Melanoma by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Ocular Melanoma therapeutics and enlists all their major and minor projects
- The report assesses Ocular Melanoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Ocular Melanoma
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Ocular Melanoma
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ocular Melanoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
A6 Pharmaceuticals LLCAcrotech Biopharma LLC
Adagene Suzhou Ltd
Ascentage Pharma Group International
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Aulos Bioscience Inc
Aura Biosciences Inc
Biogazelle NV
BioInvent International AB
BioMed Valley Discoveries Inc
Bristol-Myers Squibb Co
Byondis BV
Codiak BioSciences Inc
CytomX Therapeutics Inc
Delcath Systems Inc
Dompe Farmaceutici SpA
Ectin Research AB
Erasmus MC
Eucure (Beijing) Biopharma Co Ltd
F. Hoffmann-La Roche Ltd
Faron Pharmaceuticals Oy
Fusion Pharmaceuticals Inc
Galectin Therapeutics Inc
GSK plc
Ideaya Biosciences Inc
Immatics NV
Immunocore Holdings Plc
Inhibrx Inc
Inventiva SA
Inxmed (Nanjing) Co Ltd
iOnctura SA
ISA Pharmaceuticals BV
Kezar Life Sciences Inc
Kymera Therapeutics Inc
LightOx Ltd
Linnaeus Therapeutics Inc
Lyvgen Biopharma Ltd
Mayo Clinic
MediciNova Inc
Merck & Co Inc
Mereo Biopharma Group Plc
MiNK Therapeutics Inc
Mirati Therapeutics Inc
Modulation Therapeutics Inc
Nino Jesus University Children's Hospital
Novartis AG
Okogen Inc
Oncomatryx Biopharma SL
OncoSpherix Inc
Opna Bio SA
Osaka University
Oxular Ltd
Pfizer Inc
Prelude Therapeutics Inc
Provectus Biopharmaceuticals Inc
Regeneron Pharmaceuticals Inc
Replimune Ltd
Roca Therapeutics SAS
Sapience Therapeutics Inc
Seagen Inc
Sirnaomics Ltd
Spyre Therapeutics Inc
Statera Biopharma Inc
Takeda Pharmaceutical Co Ltd
TriSalus Life Sciences Inc
Turnstone Biologics Inc
Universitatsklinikum Erlangen
University Hospital Erlangen
University of Pittsburgh
University of Virginia
Vanquish Oncology Inc
Verastem Inc
Washington University School of Medicine